Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1

Abstract The influenza A non-structural protein 1 (NS1) is known for its ability to hinder the synthesis of type I interferon (IFN) during viral infection. Influenza viruses lacking NS1 (ΔNS1) are under clinical development as live attenuated human influenza virus vaccines and induce potent influenz...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Raveen Rathnasinghe, Mirella Salvatore, Hongyong Zheng, Sonia Jangra, Thomas Kehrer, Ignacio Mena, Michael Schotsaert, Thomas Muster, Peter Palese, Adolfo García-Sastre
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/40093ba6def04ffd8471e4167f233f58
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:40093ba6def04ffd8471e4167f233f58
record_format	dspace
spelling	oai:doaj.org-article:40093ba6def04ffd8471e4167f233f582021-11-14T12:19:10ZInterferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 110.1038/s41598-021-01780-82045-2322https://doaj.org/article/40093ba6def04ffd8471e4167f233f582021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-01780-8https://doaj.org/toc/2045-2322Abstract The influenza A non-structural protein 1 (NS1) is known for its ability to hinder the synthesis of type I interferon (IFN) during viral infection. Influenza viruses lacking NS1 (ΔNS1) are under clinical development as live attenuated human influenza virus vaccines and induce potent influenza virus-specific humoral and cellular adaptive immune responses. Attenuation of ΔNS1 influenza viruses is due to their high IFN inducing properties, that limit their replication in vivo. This study demonstrates that pre-treatment with a ΔNS1 virus results in an antiviral state which prevents subsequent replication of homologous and heterologous viruses, preventing disease from virus respiratory pathogens, including SARS-CoV-2. Our studies suggest that ΔNS1 influenza viruses could be used for the prophylaxis of influenza, SARS-CoV-2 and other human respiratory viral infections, and that an influenza virus vaccine based on ΔNS1 live attenuated viruses would confer broad protection against influenza virus infection from the moment of administration, first by non-specific innate immune induction, followed by specific adaptive immunity.Raveen RathnasingheMirella SalvatoreHongyong ZhengSonia JangraThomas KehrerIgnacio MenaMichael SchotsaertThomas MusterPeter PaleseAdolfo García-SastreNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Raveen Rathnasinghe Mirella Salvatore Hongyong Zheng Sonia Jangra Thomas Kehrer Ignacio Mena Michael Schotsaert Thomas Muster Peter Palese Adolfo García-Sastre Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1
description	Abstract The influenza A non-structural protein 1 (NS1) is known for its ability to hinder the synthesis of type I interferon (IFN) during viral infection. Influenza viruses lacking NS1 (ΔNS1) are under clinical development as live attenuated human influenza virus vaccines and induce potent influenza virus-specific humoral and cellular adaptive immune responses. Attenuation of ΔNS1 influenza viruses is due to their high IFN inducing properties, that limit their replication in vivo. This study demonstrates that pre-treatment with a ΔNS1 virus results in an antiviral state which prevents subsequent replication of homologous and heterologous viruses, preventing disease from virus respiratory pathogens, including SARS-CoV-2. Our studies suggest that ΔNS1 influenza viruses could be used for the prophylaxis of influenza, SARS-CoV-2 and other human respiratory viral infections, and that an influenza virus vaccine based on ΔNS1 live attenuated viruses would confer broad protection against influenza virus infection from the moment of administration, first by non-specific innate immune induction, followed by specific adaptive immunity.
format	article
author	Raveen Rathnasinghe Mirella Salvatore Hongyong Zheng Sonia Jangra Thomas Kehrer Ignacio Mena Michael Schotsaert Thomas Muster Peter Palese Adolfo García-Sastre
author_facet	Raveen Rathnasinghe Mirella Salvatore Hongyong Zheng Sonia Jangra Thomas Kehrer Ignacio Mena Michael Schotsaert Thomas Muster Peter Palese Adolfo García-Sastre
author_sort	Raveen Rathnasinghe
title	Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1
title_short	Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1
title_full	Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1
title_fullStr	Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1
title_full_unstemmed	Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1
title_sort	interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/40093ba6def04ffd8471e4167f233f58
work_keys_str_mv	AT raveenrathnasinghe interferonmediatedprophylacticprotectionagainstrespiratoryvirusesconferredbyaprototypeliveattenuatedinfluenzavirusvaccinelackingnonstructuralprotein1 AT mirellasalvatore interferonmediatedprophylacticprotectionagainstrespiratoryvirusesconferredbyaprototypeliveattenuatedinfluenzavirusvaccinelackingnonstructuralprotein1 AT hongyongzheng interferonmediatedprophylacticprotectionagainstrespiratoryvirusesconferredbyaprototypeliveattenuatedinfluenzavirusvaccinelackingnonstructuralprotein1 AT soniajangra interferonmediatedprophylacticprotectionagainstrespiratoryvirusesconferredbyaprototypeliveattenuatedinfluenzavirusvaccinelackingnonstructuralprotein1 AT thomaskehrer interferonmediatedprophylacticprotectionagainstrespiratoryvirusesconferredbyaprototypeliveattenuatedinfluenzavirusvaccinelackingnonstructuralprotein1 AT ignaciomena interferonmediatedprophylacticprotectionagainstrespiratoryvirusesconferredbyaprototypeliveattenuatedinfluenzavirusvaccinelackingnonstructuralprotein1 AT michaelschotsaert interferonmediatedprophylacticprotectionagainstrespiratoryvirusesconferredbyaprototypeliveattenuatedinfluenzavirusvaccinelackingnonstructuralprotein1 AT thomasmuster interferonmediatedprophylacticprotectionagainstrespiratoryvirusesconferredbyaprototypeliveattenuatedinfluenzavirusvaccinelackingnonstructuralprotein1 AT peterpalese interferonmediatedprophylacticprotectionagainstrespiratoryvirusesconferredbyaprototypeliveattenuatedinfluenzavirusvaccinelackingnonstructuralprotein1 AT adolfogarciasastre interferonmediatedprophylacticprotectionagainstrespiratoryvirusesconferredbyaprototypeliveattenuatedinfluenzavirusvaccinelackingnonstructuralprotein1
_version_	1718429282113421312

Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1

Ejemplares similares